Yue-Ming Gao

Dr. Yue-Ming Gao


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2025 in Renal Failure
Verified
Journal Article
Open access
ZSZhi Shang
Zhi Shang
SFSong-Tao Feng
Song-Tao Feng
HQHui Qian
Hui Qian
ZDZhen-Ling Deng
Zhen-Ling Deng
YWYue Wang
Yue Wang
YGYue-Ming Gao
Yue-Ming Gao
The triglyceride-glucose (TyG) index has emerged as a credible surrogate indicator of insulin resistance in recent years. This study aimed to investigate the relationship between the TyG index and the deterioration of kidney function in patients with cardiovascular-kidney-metabolic (CKM) syndrome. In this retrospective cohort study from China, 27,407 hospitalized patients with stage 1-4 CKM syndrome were consecutively included. The participants were categorized into four groups according to TyG index quartiles. The study outcome was the deterioration of kidney function, defined as a decrease in estimated glomerular filtration rate (eGFR) ≥ 40% from baseline. Restricted cubic spline (RCS) curves and multivariate Cox analysis were used for analysis. 3,248 outcome events were recorded during a mean follow-up period of 34 months. The RCS plot displayed a U-shaped curve between the baseline TyG index and the deterioration of kidney function (P for non-linear < 0.001). The baseline TyG index with the lowest hazard ratio (HR) of eGFR decline ranges from 8.65 to 9.15, with an inflection point at 8.88. After fully adjusting for covariates, HRs and 95% confidence intervals (CIs) from the lowest to highest TyG index quartile were 1.00 (reference), 0.82 (0.74, 0.91), 0.78 (0.70, 0.86), and 0.93 (0.83, 1.03), respectively. According to the Kaplan-Meier survival curve, the risk of deterioration of kidney function was elevated in the lowest and highest TyG index quartiles (log-rank test, p < 0.0001). In individuals with CKM syndrome, a non-linear U-shaped relationship existed between the baseline TyG index and the deterioration of kidney function.

29 August 2025 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
ZSZhi Shang
Zhi Shang
HZHai-Dong Zhang
Hai-Dong Zhang
HQHui Qian
Hui Qian
YGYue-Ming Gao
Yue-Ming Gao
TFTao Song Feng
Tao Song Feng
Aims: This study aimed to investigate the associations between three systemic inflammatory indices, including the systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and pan-immune-inflammation value (PIV), and the risk of renal function decline in patients with type 2 diabetes mellitus (T2DM).Methods: We consecutively enrolled 9,537 patients with T2DM hospitalized at Peking University Third Hospital. The systemic inflammatory indices were calculated from baseline blood routine indicators. Renal function decline was defined as an estimated glomerular filtration rate decreasing by ≥ 40% from baseline. All participants were categorized into tertiles according to the systemic inflammatory indices. Restricted cubic spline (RCS) curves, multivariable Cox proportional hazard regression models, and receiver operating characteristic (ROC) curves were used for analysis.Results: A total of 1,495 outcome events were recorded during the follow-up. The RCS analysis suggested a non-linear association of systemic inflammatory indices with the risk of renal function decline (P for nonlinear < 0.001). Using the lowest tertile as reference, multivariate Cox regression revealed that patients in the highest tertile of the three systemic inflammatory indices had a significantly higher risk of renal function decline (SII: HR=1.67, 95% CI=1.47–1.91, P<0.001; SIRI:HR=1.69, 95% CI=1.46–1.95, P<0.001; PIV: HR=1.58, 95% CI=1.38–1.81, P<0.001). The ROC curves showed that the SIRI was better than other two indices at predicting renal function decline.Conclusion: A significantly positive association was shown between systemic inflammatory indices and the risk of renal function decline in T2DM patients. Among these inflammatory indices, SIRI has relatively high predictive performance for renal function decline.

10 December 2024 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
YHYanfang He
Yanfang He
LMLiqian Mo
Liqian Mo
JLJuan Li
Juan Li
DLDongying Lu
Dongying Lu
JNJinlei Niu
Jinlei Niu
YGYue-Ming Gao
Yue-Ming Gao
Background: Gabapentinoids, such as gabapentin and pregabalin, are opioid substitutes commonly included in perioperative multimodal analgesia regimens. We investigated whether the initiation of gabapentin and pregabalin during the perioperative period have varying effects on the adverse renal outcomes.Methods: This study included adult participants who received surgery in the INSPIRE database. The exposure of interest was the initiation of pregabalin or gabapentin during the perioperative period. The primary outcome was renal function decline. Secondary outcomes included incident chronic kidney disease (CKD), hospital-acquired acute kidney injury (AKI), and in-hospital mortality. We conducted a propensity score to balance the baseline characteristics. Cox proportional hazard regression was used to estimate the hazard ratio (HR) of the initiation of gabapentin compared with pregabalin.Results: Among 640 pairs of pregabalin and gabapentin initiators in the matched cohort, the initiation of gabapentin was associated with a higher risk of kidney function decline (HR, 1.40; 95% confidence interval [CI], 1.04–1.89) as compared with pregabalin. After excluding participants who were diagnosed with CKD at the baseline, the initiation of gabapentin was associated with a higher risk of incident CKD (HR, 1.46; 95% CI, 1.03–2.05) as compared with pregabalin. For the in-hospital outcomes, the proportion of AKI and mortality were similar between participants initiating gabapentin and pregabalin. In addition, the risk of kidney function decline did not vary across each subgroup.Conclusion: The initiation of gabapentin during the perioperative period was associated with a higher risk of kidney function decline and incident CKD as compared with pregabalin.